Results 211 to 220 of about 75,705 (253)

Clinical applications of recombinant human growth hormone in adults

Expert Opinion on Pharmacotherapy, 1999
The main function of growth hormone (GH) is to promote linear growth during childhood; however, GH secretion persists throughout life after cessation of skeletal growth. This hormone has important physiological functions apart from growth stimulation.
P, Iglesias, J J, Díez
openaire   +2 more sources

Use of Recombinant Human Growth Hormone in Children with Thalassemia

Hormone Research in Paediatrics, 2009
<i>Background:</i> Growth failure occurs in children with chronic anemias and, in particular, in approximately 30% of those with thalassemia. <i>Methods:</i> We assessed recombinant human growth hormone (rhGH) use in a large cohort of children with thalassemia enrolled in the Pfizer International Growth Study Database (KIGS ...
Mitchell E, Geffner, Hanna, Karlsson
openaire   +2 more sources

Expanded spectrum of recombinant human growth hormone therapy

Current Opinion in Pediatrics, 2002
The efficacy of recombinant human growth hormone in the treatment of growth hormone deficiency is well established. In recent years, the use of recombinant human growth hormone as a therapeutic modality has greatly increased and has expanded beyond the realm of replacement for growth hormone deficiency.
Maria J, Henwood, Adda, Grimberg, Thomas, Moshang   +2 more
openaire   +2 more sources

Recombinant human growth hormone.

ANNA journal, 1994
Recombinant human growth hormone was initially used as replacement therapy in children with short stature. As rhGH has become more readily available, it has been tested in a variety of other individuals who have delayed growth. Children with ESRD experience significant problems with delayed growth, thus replacement therapy with rhGH has been used in ...
B, Wise, B, Case
openaire   +3 more sources

Case report: Epilepsy during the use of recombinant human growth hormone: a report on two cases and a literature review [PDF]

Frontiers in Pharmacology
Zhuangjian Xu, Yaping Ma, Ma Yaping
exaly   +2 more sources

Supercritical Fluids Processing of Recombinant Human Growth Hormone

Drug Development and Industrial Pharmacy, 2005
The aim of the study was to investigate the feasibility of precipitating recombinant human growth hormone (hGH) from aqueous solutions using conventional and modified techniques of solution-enhanced dispersion (SEDS) by supercritical fluids. The study investigated the effect on hGH stability of adding isopropanol either as a cosolvent with the original
Sitaram P, Velega, Johan, Carlfors
openaire   +2 more sources

Recombinant Human Growth Hormone for Children With Renal Failure

Advances in Renal Replacement Therapy, 1996
The pathogenesis of growth retardation in children with chronic renal failure (CRF) is clearly multifactorial. A major breakthrough in the understanding of the pathogenesis of uremic growth failure was achieved only recently by a more detailed analysis of the growth hormone (GH)/insulinlike growth factor (IGF) axis.
B, Tönshoff, R N, Fine
openaire   +2 more sources

Recombinant human growth hormone: old and novel uses

The American Journal of Medicine, 1998
Recent studies of the growth hormone insulinlike growth factor I (IGFI) axis suggest that these hormones are involved in several physiologic processes, in addition to growth. Thus, several lines of evidence indicate an increasingly important role for recombinant human growth hormone as a part of the modern therapeutic armamentarium.
N A, Tritos, C S, Mantzoros
openaire   +2 more sources

Safety of High Doses of Recombinant Human Growth Hormone

Hormone Research in Paediatrics, 1998
Recombinant human growth hormone (r-hGH) is given as substitution therapy to growth hormone-deficient children at 0.01–0.025 mg/kg/day. Higher doses are used for short stature due to Turner’s syndrome and for idiopathic short stature (approximately 0.05 mg/kg/day).
openaire   +3 more sources

Recombinant Human Growth Hormone

BioDrugs, 2008
The role of hormonal and metabolic alterations in HIV-associated lipodystrophy syndrome is not yet clear. In patients with HIV-1 undergoing antiretroviral treatment, lipodystrophy is associated with peripheral fat wasting and central adiposity, dyslipidemia, insulin resistance, and increased intramuscular fat accumulation. In HIV lipodystrophy, changes
S. Benedini, I. Terruzzi, A. Lazzarin, L. Luzi   +3 more
openaire   +3 more sources